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aBsTRacT
INTRODUCTION: Ischaemia-reperfusion injury following 
acute myocardial infarctions (AMI) is an unavoidable conse-
quence of the primary percutaneous coronary intervention 
(pPCI) procedure. A pivotal mechanism in ischaemia-reper-
fusion injury is the production of reactive oxygen species 
following reperfusion. The endogenous hormone, mela-
tonin, works as an antioxidant and could potentially mini-
mise the ischaemia-reperfusion injury. Given intracoronar-
ily, it enables melatonin to work directly at the site of 
reperfusion. We wish to test if melatonin, as an antioxi-
dant, can minimise the reperfusion injury following pPCI 
in patients with AMI. 
MATERIAL AND METHODS: The IMPACT trial is a multicen-
tre, randomised, double-blinded, placebo-controlled study. 
We wish to include 2 × 20 patients with ST-elevation myo-
cardial infarctions undergoing pPCI within six hours from 
symptom onset. The primary end-point is the Myocardial 
Salvage Index assessed by cardiovascular magnetic reso-
nance imaging on day 4 (± 1) after pPCI. The secondary end-
points are high-sensitivity troponin, creatinekinase myocar-
dial band and clinical events. 
CONCLUSION: The aim of the IMPACT trial is to evaluate the 
effect of melatonin on reperfusion injuries following pPCI. 
Owing to its relatively non-toxic profile, melatonin is an eas-
ily implementable drug in the clinical setting, and melatonin 
has the potential to reduce morbidity in patients with AMI. 
FUNDING: This study received no financial support from the 
industry. 
TRIAL REGISTRATION: www.clinicaltrials.gov, clinical trials 
identifier: NCT01172171.
The World Health Organization predicts that ischaemic 
heart disease will be the leading cause of death world-
wide by the year 2020 [1]. It is well known that infarct 
size is correlated with the short- and long-term outcome 
following acute myocardial infarction (AMI) [2]. Despite 
quick and effective treatment, the 90-day mortality fol-
lowing AMI remains 5% [3].
The most widely used and effective treatment is 
primary percutaneous coronary intervention (pPCI). 
Although rapid intervention minimises the time that the 
myocardium is without oxygen, restoring the blood flow 
and thereby the oxygen supply is not without conse-
quences. Interrupting the blood supply to an organ leads 
to tissue death, but the reperfusion in itself is also highly 
damaging. This damage is known as the ischaemia-rep-
erfusion (IR) injury. Animal studies of AMI suggest that 
lethal reperfusion injury accounts for up to 50% of the  
final infarct size in AMI [4]. Reactive oxygen species 
(ROS) or free radicals play an important role in the 
pathogenesis of cardiac IR injury. Oxidative stress is a 
consequence of the inefficient utilisation of molecular 
oxygen (O2) by cells [5]. ROS are generated as by-prod-
ucts of cellular respiration and other metabolic pro-
cesses. They damage cellular macromolecules including 
DNA, proteins and lipids [6]. 
Melatonin (N-acetyl-5-methoxytryptamine), an en-
dogenously produced hormone, is synthesised by the 
pineal gland of vertebrates. Its synthesis and release is 
stimulated by darkness and inhibited by light. Melatonin 
is known to protect against oxidative stress in cells, and 
recent publications present evidence that melatonin has 
cardio-protective properties [7]. It acts directly as a free 
radical scavenger of reactive oxygen and nitrogen spe-
cies (receptor independent) and indirectly by up-regu-
lating antioxidant enzymes and down-regulating pro- 
oxidant enzymes (receptor dependent) [8] through 
G-protein coupled receptor subtypes named MT1 and 
MT2 [9]. These potent antioxidant effects make mela-
tonin an interesting compound in the clinical setting.
The intracoronary and systemic melatonin to pa-
tients with acute myocardial infarction (IMPACT) trial 
will test the hypothesis that due to its antioxidative 
properties melatonin will protect the heart from IR in-
juries following pPCI and thereby increase myocardial 
salvage compared with placebo.
maTERial and mEThOds
The IMPACT trial is a multicentre, randomised, double-
blinded, placebo-controlled study to test the effect of in-
tracoronary and systemic administration of melatonin 
given to patients with AMI while undergoing pPCI (Fig-
ure 1). The study protocol is approved by the local eth-
intracoronary and systemic melatonin to patients  
with acute myocardial infarction:  
protocol for the imPacT trial
Natalie L. Halladin1, Sarah Ekeløf Busch1, Svend Eggert Jensen2, Henrik Steen Hansen3, Tomas Zaremba2, Jens Aarøe2,  
Jacob Rosenberg1 & Ismail Gögenur1
PROTOcOl 
aRTiclE
1) Department of 
Surgery,  
Herlev Hospital
2) Department of 
Cardiology, Aalborg 
University Hospital
3) Department of 
Cardiology, Odense 
University Hospital
  
Dan Med J
2014;61(2):A4773
 2  da n i s h m E d i c a l J O U R n a l Dan Med J 61/2  February 2014
ical committee (H-3-2010-117) and the Danish Health 
and Medicines Authority (eudraCT number: 2010-
022400-53). 
Patient selection
For inclusion and exclusion criteria, see Table 1. Patients 
will be excluded if admitted to the intensive care unit.
definitions of evaluability
1) Safety: The safety population includes all ran-
domised patients who have received the investiga-
tional product.
2) Intention to treat: This population is based on the 
initial treatment assignment and includes all 
patients who have been randomised regardless of 
whether they have received the investigational 
product or not.
3) Per protocol: This population includes all ran-
domised patients who have been treated according 
to the protocol and have completed a cardiovascu-
lar magnetic resonance imaging (CMR) within 4  
(± 1) days after pPCI. 
Primary end-point
The primary end-point will be the Myocardial Salvage In-
dex (MSI). It will be assessed by CMR on day 4 (± 1) after 
pPCI. MSI will be calculated as follows: (area at risk 
(AAR) – infarct size)/AAR. AAR will be assessed by short 
tau inversion recovery T2-weighted (T2-STIR) imaging. 
On T2-STIR sequence, oedematous myocardium appears 
brighter, and the AAR will be traced manually on short-
axis images. In cases of T2-STIR images being of poor di-
agnostic quality, early gadolinium enhancement (EGE) 
images will be used for manual tracing of AAR. EGE will 
be acquired as post-gadolinum contrast steady-state 
free precession (SSFP) scans.
Infarct size will be measured by inversion recovery 
gradient echo sequence (late gadolinium enhancement 
(LGE) imaging). 
The LGE imaging will be started about ten minutes 
after intravenous (IV) administration of 0.2 mmol/kg 
gadolinium-based contrast. The areas of LGE will be 
quantified on short-axis images using automatic thresh-
olding by the CMR-analysis software. The amount of  
microvascular obstruction, which appears as dark areas 
surrounded by enhanced infarcted myocardium, will be 
assessed manually from LGE images and will be included 
in the infarct size.
Left ventricular (LV) volumes, mass and systolic 
function will be assessed by SSFP imaging. Quantifica-
tions will be performed manually in short-axis images. 
Papillary muscles will be included in the LV cavity vol-
ume.
image acquisition protocol
Standard imaging planes will be planned from localizer 
(scout) scans. The following images will be acquired: 
SSFP short-axis images covering the entire LV from the 
atrioventricular plane to the apex at 8/0 mm (slice thick-
ness/slice gap), SSFP long-axis images in 2-, 3-, and 
4-chamber views (8 mm slice thickness). T2-STIR images 
in short-axis (8/0 mm) will be obtained. Afterwards, gad-
olinium-based contrast will be given IV. Then, SSFP im-
ages will be repeated (EGE imaging). Lastly, LGE short-
axis images (8/0 mm) and LGE long-axis images in 2-, 3-, 
and 4-chamber views (8 mm slice thickness) will be ac-
quired.
Secondary end-points
– Blood samples for assessment of cardiac enzymes 
(high-sensitivity troponin T (hs-TnT) or high-sensitiv-
ity troponin I (hs-TnI)). Hs-TnT/hs-TnI will be 
measured in a peripheral blood sample preopera-
tively and 6, 24, 48, 72 and 96 hours after pPCI. 
Hs-TnT/hs-TnI will be calculated as the area under 
the curve (AUC).
– Creatinekinase myocardial band, (CK-MB) will be 
measured in a peripheral blood sample preopera-
tively and 6, 24, 48, 72 and 96 hours after pPCI. 
– Plasma melatonin and markers of oxidative stress: 
advanced oxidative protein products, malondialde-
hyde and myeloperoxidase will be collected during 
hospital admission 24 h post pPCI.
– Clinical events occurring within the first 90 days 
after pPCI: Sustained ventricular arrhythmias, 
resuscitation after cardiac arrest, cardiogenic shock, 
revascularization of a new coronary artery, coro- 
nary artery bypass graft, major bleedings, re-infarc-
tion, stent thrombosis, cardiac and non-cardiac 
re-hospitalization, and death.
FigURE 1
Percutaneous coronary intervention procedure. The cardiologist can visu-
alize the patient’s coronary arteries in the screen using contrast media.
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study design
Patients who meet the inclusion criteria will be ran-
domised to either melatonin (M-5250, Sigma-Aldrich, St. 
Louis, Missouri, USA) or placebo (isotonic saline). Pa-
tients randomised to melatonin will receive a total dose 
of 50 mg, 1 mg given as an intracoronary (IC) bolus (10 
ml 0.1 mg/ml) and 49 mg (490 ml 0.1 mg/ml) given IV in 
a peripheral vein. A bolus of either melatonin or placebo 
will be given through the PCI-guiding catheter within the 
first 60 seconds after restoring the blood flow to the in-
farct-related artery. The 490 ml melatonin or placebo 
will be given over a time period of six hours commencing 
immediately after pPCI. pPCI will be performed accord-
ing to the standard clinical practice and at the operator’s 
discretion. Any medication given in relation to the pPCI 
will be according to the standard guidelines at the trial 
centres.
Blood samples will be collected before the reperfu-
sion and 6, 24, 48, 72 and 96 hours post-intervention. 
On day 4 (± 1) after pPCI, the patients will undergo 
CMR to assess the primary end-point. 
At 90 days post-intervention, the medical journals 
will be obtained in order to register any clinical events in 
the 90-day period.
sample size
Based on previous results [10] that tested the cardiopro-
tective effect of exenatide following coronary occlusion 
and subsequent reperfusion in patients undergoing 
pPCI, we assume that the average salvage index meas-
ured by CMR will be 0.62 with a standard deviation of 
0.16. With a type 1 error at 5% and a type 2 error at 
20%, and the smallest effect that would be important to 
detect at 25%, it is possible by CMR to detect a differ-
ence in infarct size (MSI) between the two groups by in-
cluding 17 patients into each group. We have decided to 
include 20 patients into each group.
statistical analysis
Regarding the primary end-point, the following data will 
be reported for the two groups in the CMR analysis: MSI 
defined as (AAR-infarct size)/AAR, myocardial salvage 
(AAR-infarct size), infarct size (absolute and % of AAR 
and % of LV), AAR (absolute and % of LV), LV dimensions 
(mass in diastole, end-diastolic volume, end-systolic vol-
ume), left ventricular function (stroke volume and ejec-
tion fraction) and the amount of microvascular obstruc-
tion (absolute and % of AAR and % of LV).
Regarding the primary endpoint MSI, normality of 
the data will be tested using the Kolmogorov-Smirnov 
test, and parametric or non-parametric statistics will be 
used accordingly. If data are parametric, we will test for 
statistical significance using unpaired t test. Data will be 
described using mean and standard deviation. If data are 
non-parametric, we will test for statistical significance 
for two independent samples using the Mann-Whitney 
U test. Data will be described using medians and ranges. 
Categorical variables will be analysed using either 
Fisher’s exact test or the χ2-test. Generally, a two-sided 
p value of < 0.05 will be considered statistically signifi-
cant. Data will be analysed using SPSS/PC+ package 20.0 
(SPSS Inc., Chicago, IL, USA).
secondary end-points
Data will be analysed according to the same principles as 
described for the primary endpoint.
Randomisation and blinding
The randomisation list is generated by the hospital phar-
macy, Herlev, Denmark, at which the melatonin is also 
tested for sterility and packaged in glass bottles. There 
are two sealed envelopes containing the randomisation 
code for each patient; one used for randomisation by 
the assisting nurse at the time of pPCI; the other to be 
kept with the patients case report form to double-check 
allocation when the study is terminated. The assisting 
nurse will also be responsible for mixing the melatonin 
powder with isotonic saline if the patient is randomised 
to active treatment. Thereby the investigator, the op-
TaBlE 1
Inclusion and exclusion criteria.
inclusion criteria Exclusion criteria
Adults > 18 years of age
pPCI initiated within 6 h from symptom onset
Having an electrocardiogram indicative of an acute 
ST-elevation myocardial infarction showing: 
≥ 0.2 mV in V2 or V3 and/or        
≥ 0.1 mV in the other leads 
for men < 40 years: ≥ 0.25 mV in V2-V3
Occlusion of a large (> 2 mm) infarct-related coro-
nary artery with TIMI 0-1
Being willing and able to provide informed con-
sent after written and oral information
Known prior myocardial infarction
Prehospital thrombolysis
ASA class ≥ 4
> 1 artery with coronary stenosis that requires 
treatment
Known history of renal failure (GFR < 60 ml/
min./1.73 m2 p-cratinin > 200 μmol/l)  
Known history of autoimmune diseases (systemic 
lupus erythematosus, mulitple sclerosis, rheuma-
toid arthritis, type 1 diabetes mellitus)
Servere concurrent illness with reduced short-
term prognosis (e.g. terminal cancer, terminal 
AIDS, severe infection)
Atrial fibrillation before or after pPCI
Pregnancy
Breastfeeding
Fertile woman < 12 months since menopause or 
nonsterilised) 
Cardiogenic shock
BMI > 40 kg/m2 
Contraindications for CMR (pacemaker, parts of 
metal in the body and claustrophobia)
ASA class = The American Society of Anesthesiologists Physical Status classification; BMI = body mass 
 index; CMR = cardiovascular magnetic resonance imaging; GFR = glomerular filtration rate; pPCI = 
 primary percutaneous coronary intervention; TIMI = thrombolysis In myocardial infarction.
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erating cardiologist and the patient will be blinded 
throughout the study. The analysis of the CMR will also 
be kept blinded, and the overall statistical analyses will 
be performed without knowing which treatment group 
the patients belong to. The allocation code will be re-
vealed only after all analyses are completed.
The IMPACT trial has a safety committee. The com-
mittee consists of three senior consultant doctors spe-
cialising in cardiology, anaesthesiology and surgery. The 
safety committee is not in any way involved in the trial, 
but will be contacted if a study subject experiences a 
ser ious adverse reaction or a serious adverse event. If 
they find it plausible that the serious adverse reaction/
event is directly related to the trial, they can have the 
subject unblinded, and ultimately the trial might be ter-
minated.
Trial registration: www.clinicaltrials.gov, Clinical trials 
identifier: NCT01172171.
discUssiOn
One of the known mechanisms involved in IR injury is 
the massive generation of ROS [11]. Melatonin, one of 
the most potent endogenous antioxidants [12], is highly 
lipid-soluble, but also soluble in aqueous solutions. Thus, 
melatonin readily enters all cells and subcellular com-
partments and cross morphophysiologic barriers [13] 
and exhibits its antioxidant functions.
Mitochondria are known to be intimately involved 
in the processes that lead to cell death following reper-
fusion [14]. Permeability transition in the mitochondria 
is caused by the opening of the mitochondrial perme-
ability transition pore (mPTP) [15]. Massive mPTP open-
ing results in mitochondrial depolarisation, swelling and 
rupture of the external mitochondrial membrane and ef-
flux of cytochrome c and other proapoptotic factors that 
may lead to either apoptosis or necrosis. It has been 
suggested that mPTP remains closed during the isch-
aemic period, and at reperfusion there is an influx of 
Ca2+ into the mitochondria resulting in a burst of ROS 
production. Identification of agents that can protect the 
heart from the damaging effects of mPTP is of consider-
able importance in attenuating IR injuries [15]. Mela-
tonin directly inhibits the mPTP [16], and this makes me-
latonin an apparent choice when considering possible 
treatments with regard to IR injuries.
Melatonin is relatively non-toxic [17]. Doses of 
1,000 mg daily for one month have been given to hu-
mans and the only reported adverse effect was drowsi-
ness [17]. In a recent systematic review, the most fre-
quently reported side effects were headache, dizziness, 
nausea and drowsiness, but with frequencies compar-
able to placebo [18]. We have chosen the 50 mg mela-
tonin dose as we have previously shown (unpublished 
data) that this dose significantly reduced the cardiac 
morbidity and markers of myocardial injury after major 
vascular surgery.
With regard to our primary outcome, we chose MSI 
assessed by CMR. CMR is uniquely able to integrate in a 
single examination an accurate quantitative assessment 
of LV function, structural abnormalities of the myocar-
dial tissue including oedema, infarct size and myocardial 
salvage as well as its microvascular status. Therefore, 
CMR has a potential as the main diagnostic tool in AMI 
by providing information on the stage, degree and ex-
tent of reversible and irreversible myocardial injury [19, 
20]. Thus, we find that CMR is the best available method 
for the determination of our primary outcome. 
cOnclUsiOn
In conclusion, we intend to examine the effect of mela-
tonin in patients with AMI undergoing pPCI. If the results 
are positive, this simple treatment may be included for 
pPCI with revascularisation in a larger scaled study, and 
it would be of interest to examine the effect of mela-
tonin given as a prehospital treatment to further reduce 
the IR injury. The diversity of melatonin’s physiological 
functions and treatment effects are continuously being 
investigated in both animal and human studies. To date, 
the effect of IC melatonin in patients with AMI has not 
yet been studied.
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